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Abstract: The older senior is at high risk for osteoporosis. It is important for healthcare providers 
to be fully aware of the potential risks and beneﬁ  ts of diagnosing and treating osteoporosis in the 
older senior population. Data indicate that bone mineral density testing is under-utilized and drug 
therapy is often not initiated when indicated in this population. Bone mineral density testing with 
central dual energy x-ray absorptiometry is essential and cost-effective in this population. All 
older seniors should be educated on a bone-healthy lifestyle including age-appropriate weight-
bearing exercise and smoking cessation if necessary. It is important to remember that falls play 
a very important role in the risk for osteoporotic fractures, especially in the older senior. All 
older seniors should be evaluated annually for falls and strategies should be implemented to 
reduce fall risk in this population. The risk for vitamin D insufﬁ  ciency and deﬁ  ciency is high 
in the older senior and can contribute to falls and fractures. Adequate intakes of calcium and 
vitamin D are important and deﬁ  ciencies need to be treated. Data on osteoporosis drug therapy 
in the older senior are lacking. Based on data from subgroup analyses of large osteoporosis 
trials in postmenopausal women, current osteoporosis therapies appear safe and efﬁ  cacious in 
the older senior and most will live long enough to derive a beneﬁ  t from these therapies. Further 
studies are needed in older seniors, especially men, to better understand the risks and beneﬁ  ts 
of pharmacologic therapy for the management of osteoporosis.
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Introduction
Osteoporosis is, for the most part, a disease of aging. Age is an independent risk 
factor for the development of osteoporosis and osteoporotic fractures (low-trauma 
fractures) and the prevalence of osteoporosis rises dramatically with age.1 According 
to National Health and Nutrition Examination Survey (NHANES) data, the prevalence 
of osteoporosis based on reduced hip bone density was estimated at 4% in women 
50 to 59 years of age compared to 44% in women 80 years of age and older.2,3 The 
number of seniors at risk for osteoporosis is going to continue to increase with the 
aging of society. It is estimated that the number of people in the United States (US) 
over the age of 65 years will increase from 36.8 million in 2004 to 54.6 million by 
2020.4 During the same time period, the number of people age 85 years and older 
will increase from 5.1 million to 7.3 million. It has been estimated that in the US the 
number of hip fractures and their associated costs could double or triple by the year 
2040.5 These statistics are similar worldwide.6
The risk for low-trauma fractures goes up substantially with age. Hip fracture risk, 
in particular, rises exponentially after age 70 years.7–9 In one study, the incidence rate 
for hip fractures was estimated at 1.6 per 1000 person-years for 65-year-old white 
women compared to 35.4 per 1000 person-years in 95-year-old women.9 In 2004, 
there were 329,000 hospital discharges for hip fracture with 125,000 occurring in 
patients  85 years of age compared to 116,000 in patients 75 to 84 years of age and 
48,000 in patients between 65 and 74 years of age.10 Low-trauma fractures, especially Clinical Interventions in Aging 2009:4 122
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hip fractures, signiﬁ  cantly increase health care costs, and 
contribute to an increase in morbidity and mortality in the 
older senior.11–16 After hip fracture, only half of patients return 
to their pre-fracture ability level.12 In addition, 3% to 5% of 
patients die during the initial hospitalization for hip fracture, 
and approximately 20% to 40% die within 1 year.12,17
Data indicate that older seniors with osteoporosis are 
frequently not treated with drug therapy.18–22 A prospective 
cross-sectional study of nursing home residents (average 
age ∼80 years) with known osteoporosis or recent hip frac-
ture revealed that 69% were receiving calcium and 63% 
vitamin D, but only 19% a bisphosphonate.23 Overall, only 36% 
were receiving any prescription medication or hip protector for 
osteoporosis. In a cross-sectional database analysis of newly 
admitted nursing facility residents (79.6%  75 years of age 
and 36.6%  85 years of age), only 9.1% were receiving an 
antiresorptive agent or calcium and vitamin D supplementation 
despite an expected high prevalence of osteoporosis in this 
population.24 Osteoporosis medication use was evaluated in 
4430 patients who sustained a hip, wrist or humeral fracture and 
were admitted to a nursing home from 1995 to 2004.19 Mean age 
of the study population was 82.7 years. Only 11.5% of patients 
received any type of osteoporosis medication within 12 months 
of the fracture. The most common therapies prescribed were 
calcitonin (56%) followed by bisphosphonates (35.1%). 
Osteoporosis medication use within the previous 12 months 
was the best predictor of subsequent treatment (hazard ratio 
[HR] = 19.46; 95% conﬁ  dence interval [CI], 16.02–23.63). 
A retrospective study, using a claims database, of postmeno-
pausal women who sustained a distal radial fracture revealed 
that the rate of treatment for osteoporosis decreased signiﬁ  cantly 
with increasing age (p   0.001), with 36% of patients age 55 
to 59 years receiving treatment compared to 21.4% (age 75–79 
years), 25.7% (age 80–84 years), 9.1% (age 85–89 years), 4.2% 
(age 90–94 years), and 4.7% (age   95 years).18
The management of osteoporosis can be challenging in 
the older senior. Limited data regarding efﬁ  cacy of drug 
therapy, multiple co-morbid conditions, increased risk for 
side effects from medications, and ﬁ  nancial constraints have 
contributed to a discrepancy between the number of older 
seniors at risk for osteoporosis and the number being evalu-
ated and treated. It is important for healthcare providers to be 
fully aware of the potential risks and beneﬁ  ts of diagnosing 
and treating osteoporosis in the older senior population.
Pathophysiology of fractures
The two main factors that impact risk for a low-trauma 
fracture are skeletal fragility (eg, low bone density and 
poor bone quality) and falls. The risk for low bone density 
increases with age and signiﬁ  cantly impacts bone strength. 
While difﬁ  cult to measure, bone quality (alterations in bone 
geometry and microarchitecture) is also thought to be reduced 
with aging and contributes to compromised structural integ-
rity of bone.25 In the older senior, falls become a greater factor 
in the risk for fractures.
It is estimated that 50% of seniors 85 years of age and 
older will fall at least once per year and half of those who 
fall will do so more than once.26 Approximately 5% of these 
falls result in a fracture.26 The risk for falls increases with 
advanced age.27,28 According to data from the National Center 
for Injury Prevention and Control, US seniors age 85 years 
of age and older had a much higher crude non-fatal and 
fatal fall rate compared to seniors age 65 to 69 years (non-
fatal: 10.7 vs 2.5 per 100 persons and fatal: 143.7 vs 9.2 per 
100,000 persons).29
The more one falls, the greater their risk for fracture. 
Falls and fracture risk were evaluated in a large prospective 
cohort study of frail elderly in residential care facilities (mean 
age 85.7 years).28 Fall and fracture rates of 214 and 12.1 per 
100 person years, respectively, were documented over the 
median 705 day follow-up period. Eighty-two percent of 
the fractures could be attributed to a fall. Subjects who fell 
frequently ( 3.08 falls per person-year) were 3 times more 
likely to suffer a fracture compared to subjects who did not 
fall (incident risk ratio = 3.35; 95% CI, 2.38–4.72). Fall rate 
was an independent predictor of fracture risk (p   0.001).
The risk for falls increases with advanced age due to a 
variety of factors. Impaired balance, gait and mobility; and 
poor vision, reduced muscle strength, and impaired cognition 
have all been found to be strong risk factors for falls.26,30 In 
addition, the use of multiple medications, especially psycho-
active medications such as benzodiazepines, antidepressants, 
and antipsychotics, and certain co-morbid disease states such 
as stroke, Alzheimer’s dementia and Parkinson’s disease, 
have been strongly associated with falls and fractures.26,30–32 
The ability to adapt to falls also decreases with aging. Older 
seniors are more likely to sustain a hip fracture because they 
tend to fall backwards or sideways; leaving them unable to 
catch themselves or break their fall.33,34
Vitamin D also plays an important role in bone strength 
and falls, with detrimental effects found in patients with 
vitamin D insufﬁ  ciency and deﬁ  ciency. It is estimated that 40% 
to 100% of US and European older men and women living 
in the community are insufﬁ  cient or deﬁ  cient in vitamin D.35 
A recent study of long-term care residents (mean age 85 years) 
found that although 91% of patients were receiving vitamin D Clinical Interventions in Aging 2009:4 123
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supplementation, 49.4% were vitamin D insufﬁ  cient and 16% 
were found to be vitamin D deﬁ  cient.36 In an older ambulatory 
population (mean age 78 years) where most of the patients were 
taking vitamin D supplements, 81% were found to be either 
insufﬁ  cient or deﬁ  cient in vitamin D.37
Reduced 25-hydroxy vitamin D (25(OH) vit. D) concentra-
tions lead to reduced calcium absorption, secondary hyperpara-
thyroidism, an increase in bone resorption, and consequently 
fractures.38 A study of 119 community dwelling women (mean 
age 71 years) with a history of vertebral fracture found that 
mean bone turnover markers were signiﬁ  cantly elevated in the 
vitamin D insufﬁ  cient patients compared to those sufﬁ  cient in 
vitamin D.39 In addition, bone mineral density (BMD) at the hip 
was signiﬁ  cantly lower in the vitamin D insufﬁ  cient patients than 
those sufﬁ  cient in vitamin D (p   0.01). A positive correlation 
has also been observed elsewhere between serum 25(OH) 
vitamin D and BMD in older women, such that vitamin D 
deﬁ  ciency is associated with lower femoral neck BMD.38
Vitamin D is essential to maintain muscle function and 
strength, especially in the weight-bearing muscles of the 
lower body required for balance and walking. Vitamin D and 
its metabolites bind to skeletal muscles, affecting muscle cell 
growth and metabolism.40,41 A lack of vitamin D can cause 
muscle weakness and falls.40,41 Muscle weakness is typically 
in the proximal muscle groups and is characterized by a 
feeling of heaviness in the legs, tiring easily, and difﬁ  culty 
in climbing stairs and rising from a chair.40 Multiple studies 
have documented that vitamin D deﬁ  ciency in older seniors 
is associated with reduced handgrip strength, inability to 
climb stairs, reduced walking distance, impaired leg exten-
sion power, and less outdoor activity.40 An Australian study 
of nursing home and hostel patients (median age 84 years) 
found that residents who fell had signiﬁ  cantly lower 25(OH) 
vitamin D concentrations than other residents (p = 0.02).41
Screening for osteoporosis
The prevalence of osteoporosis is high in the older senior; 
however, many do not realize they have the disease. 
According to NHANES data from 1988 to 1994, only 1.3% 
and 1.6% of men and 12.1% and 9.7% of women age 75 to 
84 years and 85 years and older, respectively, reported they 
had osteoporosis.42 However when tested, 6.4% and 13.7% 
of men and 32.5% and 50.5% of women, respectively, had 
the disease. BMD testing using central dual-energy x-ray 
absorptionmetry (DXA) is the gold standard for identifying 
patients with osteoporosis. BMD testing is cost-effective in 
the older senior who is at highest risk for osteoporosis and has 
been show to signiﬁ  cantly inﬂ  uence the decision to initiate 
drug therapy.20,43,44 In a report by the US Preventive Services 
Task Force, it was estimated that only 75 and 143 women 
between 75 and 79 years of age would need to be screened 
(and subsequently treated if necessary) to prevent one 
vertebral fracture and one hip fracture, respectively.45 This 
is in comparison to needing to screen 458 and 1856 women 
between the ages of 60 and 64 years. Universal bone density 
screening in women 65 years of age and older followed 
by treatment with alendronate was found to be more cost-
effective with increasing age.43 The cost per quality adjusted 
life year (QALY) gained was approximately US$43,000 
for 65-year-old women, US$5600 for 75-year-old women 
and cost saving for women 85 or 95 years of age or older. 
A similar analysis of the cost-effectiveness of densitometry 
followed by treatment in men revealed a cost per QALY 
gained of  US$50,000 in all men 65 years of age or older 
with a prior clinical vertebral fracture and men 80 years of age 
or older regardless of prior fracture.44 In the United Kingdom 
(UK), treatment with alendronate was cost effective (thresh-
old value of £30,000 or  43,000/QALY gain) in women 
60 years of age or older with osteoporosis (T-score –2.5 
or below) and in women 50 years or older with a previous 
low-trauma fracture.46 Treatment with alendronate was cost 
saving in women 80 years or older with a prior low-trauma 
fracture. While alendronate was most cost effective (due to 
generic availability), most other therapies for osteoporosis 
were found to be cost effective in women aged 70 years and 
older with osteoporosis.
While guidelines recommend BMD testing in all women 
65 years of age and older and men 70 years of age and 
older regardless of clinical risk factors, many older seniors 
do not receive a central DXA test.5,20,47,48 In the year 2000, 
the US Medicare system paid for 1.75 million bone density 
tests, which would account for only approximately 9% of 
US women over the age of 65 years.49 Similar results were 
seen in a study of bone mass measurement claims in US 
Medicare beneﬁ  ciaries over the age of 65 years.50 From 1999 
to 2005, only 30% of women and 4.4% of men underwent 
central DXA testing. According to a retrospective study of 
US Medicare administrative claims between 1999 and 2001, 
bone density screening of eligible women decreased with 
advancing age.48 Twenty-seven percent of eligible women 
between 66 and 70 years of age received bone density testing 
compared to only 16% of women age 81 to 85 years of age 
and 9.7% of women between 86 and 90 years of age. While 
testing rates were high in an academic geriatric practice, 
older seniors and those with lower functional status were 
less likely to be tested.51Clinical Interventions in Aging 2009:4 124
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Central DXA BMD testing is under-utilized in the older 
senior. Logistical and cost issues associated with central DXA 
testing in institutionalized older seniors may be one of the 
main reasons. Calcaneal or forearm BMD measurements using 
portable quantitative ultrasound or peripheral DXA devices 
can be an alternative to assist with risk stratiﬁ  cation in this 
population.52–55 In addition, the 10-year probability for hip or 
major osteoporotic fracture can be calculated using selected 
clinical risk factors in the absence of BMD results with the 
World Health Organization (WHO) Fracture Risk Assess-
ment Tool (FRAX). There are several international versions 
of this tool and four versions available speciﬁ  cally for Asians, 
Caucasians, Blacks, and Hispanics residing in the US. This 
tool is accessible at http://www.shef.ac.uk/FRAX/.56
For the community-dwelling older senior, it is possible 
that the under-utilization of BMD testing is due to the miscon-
ception that it is too late to make an impact on osteoporosis 
in this population. It is important for healthcare providers to 
realize osteoporosis risk and adverse outcomes from fractures 
increase with age and that evidence consistently shows that 
those at highest risk for fracture are the ones that beneﬁ  t most 
from interventions such as pharmacological therapy.57
Diagnosis of osteoporosis
The diagnosis of osteoporosis is based on a low BMD T-score 
at the lumbar spine, total hip or femoral neck.5 A BMD T-score 
of –1.0 or higher (ie, a BMD within 1 standard deviation of 
that expected for a young, healthy adult of the same sex) 
is considered normal. A T-score between –1.0 and –2.5 is 
considered osteopenia, and a T-score of –2.5 or lower (ie, 
2.5 or more standard deviations below the expected BMD) 
is considered osteoporosis. Patients with a T-score of –2.5 
or lower and evidence of low-trauma fractures have severe 
osteoporosis. A diagnosis of osteoporosis may also be made 
clinically in at-risk individuals based on the presence of a 
low-trauma fracture.5
Evaluation of the older senior
with osteoporosis
All older seniors should undergo an investigation for second-
ary causes for osteoporosis as a part of the full evaluation 
of osteoporosis. Routine laboratory testing recommended 
for identifying the most common secondary causes for 
osteoporosis in older seniors is summarized in Table 1. 
Vitamin D status is important to assess on a yearly basis 
in the older senior. There is, however, no universal agree-
ment on what 25(OH) vitamin D concentrations constitute 
deﬁ  ciency or insufﬁ  ciency. Currently, most experts in the 
US agree that concentrations  75 nmol/L ( 30 ng/mL) 
deﬁ  ne vitamin D sufﬁ  ciency, concentrations between 50 
and 72.5 nmol/L (20–29 ng/mL) deﬁ  ne vitamin D insufﬁ  -
ciency, and concentrations  50 nmol/L ( 20 ng/ml) deﬁ  nes 
vitamin D deﬁ  ciency.35
All older seniors should be asked annually about the 
occurrence of falls, as patients who fall are at an increased 
risk for future falls. Any patient that reports a single fall 
should undergo a basic evaluation of gait/balance (eg, “Get 
Up and Go Test”).58 Two or more falls or one fall with injury 
within the past year should prompt a thorough fall risk assess-
ment.59 Items that should be included as part of a fall risk 
assessment are summarized in Table 2.58–60
Treatment
Bone-healthy lifestyle
Exercise, fall prevention and smoking cessation in the older 
senior with osteoporosis should be encouraged whenever 
Table 1 Suggested routine laboratory tests for the evaluation of secondary causes of osteoporosis in the older senior
Laboratory test Secondary cause
Serum creatinine and blood urea nitrogen  Chronic kidney disease
Serum alkaline phosphatase Paget’s disease; osteomalacia
Serum thyroid-stimulating hormone concentration Hyperthyroidism or over-supplementation of thyroxine
Serum calcium and phosphorous concentrations Vitamin D deﬁ  ciency; malabsorption
24-hour urinary calcium Excessive urinary excretion of calcium
Total serum testosterone (men) Hypogonadism
25-hydroxy vitamin D Vitamin D insufﬁ  ciency/deﬁ  ciency
Intact serum parathyroid hormone Primary or secondary hyperparathyroidism
Serum protein electrophoresis Multiple myeloma
Complete blood count  Leukemia
Liver function tests  Chronic liver diseaseClinical Interventions in Aging 2009:4 125
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possible to help preserve BMD and reduce fracture risk 
(Table 3).58–66 Data show that aerobic, weight bearing and 
resistance exercise increases BMD of the spine and that 
walking alone increases BMD of both the hip and the spine 
in postmenopausal women.62 This type of exercise should 
be encouraged in older seniors too. However, a medical 
examination is recommended to make sure the patient is 
safe to exercise and to assess muscle strength, range of 
motion, level of physical activity, ﬁ  tness, gait and identify 
balance problems.61 Exercise regimens should be tailored 
to individual patient abilities. Loading exercises that can 
be beneﬁ  cial to the hip can result in compression fractures 
Table 2 Fall risk assessment in the older senior58–60
Fall risk assessmenta
Basic fall history (eg, number and circumstances surrounding falls)
Medication review: eliminate unnecessary or inappropriate psychoactive medications including antipsychotics, anxiolytics, hypnotics, antidepressants, 
muscle relaxants, anticholinergics and narcotics, and medications such as diuretics or certain antihypertensives known to cause postural hypotension
Document alcohol consumption
Document acute or chronic medical conditions
Document orthostatic vitals (blood pressure and pulse)
Visual acuity testing
Basic gait, balance, and strength evaluation (eg, basic neurological exam to evaluate muscle strength, cerebellar function and peripheral sensory 
function;   “Get Up and Go Test”b)
Cognitive status (eg, Mini-Mental State Exam)
Evaluation of home and personal safety
aRecommended assessment for patients with two or more falls or one fall with injury within the past year.
b“Get Up and Go Test”: patients are instructed to stand from a seated position without using their hands, walk 10 feet, turn around, return to the chair and sit down. Patients 
that take longer than 30 seconds are at a higher risk for falls.
Table 3 Recommendations for a bone-healthy lifestyle in the older senior
Intervention
Exercise61–63
Recommendations Comments
•   Moderate-intensity aerobic physical activity
for  30 minutes for 5 days/week.
•   8–10 exercises using the major muscle
groups for  2 days/week
•    10 minutes of activities to maintain or
increase ﬂ  exibility for  2 days/week
•   Exercises to maintain/improve balance
in older seniors with substantial fall risk
A physical examination should be
performed prior to starting an exercise 
regimen.   The exercise regimen should 
be tailored to each individual patient.
Fall prevention58–60,64–66 •   Physical activity (as above)
•   Home environment modiﬁ  cations
•   Vision assessment
•   Use of ambulation-assistive devices
•   Treatment of cardiovascular causes of falls
•   Eliminating unnecessary medications
•   Vitamin D supplementation
Calcium5,71,72 •   1200–1500 mg calcium divided two
to three times daily
Older seniors taking proton pump 
inhibitors may beneﬁ  t from calcium 
citrate. Patients should be counseled 
regarding possible side effect of 
constipation.
Vitamin D5,35 To avoid deﬁ  ciency
•     800–1000 IU vitamin D3 daily OR
•   50,000 IU vitamin D2 every 2–4 weeks
To treat deﬁ  ciency
•   50,000 IU vitamin D2 every week for
8–16 weeks
Abbreviation: IU, international units.Clinical Interventions in Aging 2009:4 126
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of the spine, so the intensity/resistance of exercise might 
need to be adjusted to BMD.61 An example daily exercise 
regimen recommended for seniors is: 1) a 5- to 10-minute 
warm-up session of walking, stretching, or calisthenics; 
2) a 15- to 20-minute muscle conditioning program (eg, 
weight training); 3) 15 to 20 minutes of aerobics (eg, 
fast walking, jogging, stair stepping, biking, or vigorous 
dancing); and 4) a 5- to 10-minute cool-down session (eg, 
walking or stretching).61 Recently published guidelines from 
the American Heart Association recommend that all seniors 
(65 years and older) need moderate-intensity aerobic physi-
cal activity for at least 30 minutes on 5 days of each week, 
or vigorous-intensity aerobic activity for at least 20 minutes 
on 3 days of each week.63 The guideline also includes rec-
ommendations for 8 to 10 exercises using the major muscle 
groups on 2 or more days per week, at least 10 minutes of 
activities to maintain or increase ﬂ  exibility on at least 2 days 
of each week, and exercises to maintain or improve balance 
in those with substantial risk of falls.63 Although not neces-
sarily targeted for the “older senior,” these recommendations 
come from data that regular physical activity reduces risk 
of many diseases, plays a therapeutic role in diseases such 
as osteoporosis, reduces risk of falls and injuries from falls, 
and reduces functional limitations. Thus, exercise and muscle 
strengthening should still be encouraged as much as possible 
in the older senior.
Other methods of preventing falls include home envi-
ronment modiﬁ  cations (eg, removing loose rugs or exten-
sion cords, repairing rickety stairs, adding grab bars in the 
bathroom, increasing lighting), assessing vision and treating 
any remedial visual abnormalities, assessing need for ambu-
lation-assistive devices (eg, canes and walkers), treatment of 
cardiovascular causes of falls (eg, orthostatic hypotension, 
arrhythmias) and eliminating medications that can increase 
risk of falls (eg, antipsychotic agents, benzodiazepines, 
antidepressants, antihypertensives, diuretics).58
Smoking cessation is also recommended for the older 
senior with osteoporosis. One year of smoking cessation has 
been shown to signiﬁ  cantly increase BMD in the femoral 
trochanter (p = 0.02) and total hip (p = 0.03) relative to con-
tinuation of smoking in postmenopausal women.67 Moreover, 
smoking cessation has been found to reduce the risk of hip 
fracture compared to continuation of smoking in non-elderly 
women, although the beneﬁ  t was not evident until 10 years 
after cessation.68 Despite a lack of data in older seniors and 
that the beneﬁ  ts of smoking cessation for osteoporosis may 
be delayed, the other health beneﬁ  ts of smoking cessation (eg, 
vascular, pulmonary) make it important for all older seniors.
Hip protectors
External hip protectors are specialized undergarments 
designed to pad the area surrounding the hip decreasing 
the force of impact from a sideways fall. Individual studies 
evaluating the effectiveness of these products have dem-
onstrated conﬂ  icting results.69 Poor compliance is the main 
drawback with these devices, as patients tend to ﬁ  nd them 
uncomfortable and cosmetically unappealing. A recent meta-
analysis of randomized controlled trials demonstrated no 
beneﬁ  t from hip protectors in community-dwelling seniors.69 
In addition, there was no difference in hip fracture rates in 
a large, multicenter, randomized controlled trial of nursing 
home residents.70 These data indicate that hip protectors are 
ineffective and should not be recommended alone for the 
prevention of hip fractures.
Calcium and vitamin D
All patients with osteoporosis, regardless of age, should 
receive adequate calcium and vitamin D (Table 3).5,35,71,72 
Diet alone is usually not adequate to maintain recommended 
intakes of calcium and vitamin D, and supplementation is 
almost always necessary. Many studies have evaluated the 
effects of calcium and vitamin D on BMD and fractures 
and vitamin D on falls in older adults. A meta-analysis of 
calcium and calcium/vitamin D supplementation found that 
the supplements signiﬁ  cantly reduced fracture risk by 12% 
(p = 0.004) and reduced bone loss by 0.54% (p   0.0001) at 
the hip and 1.19% (p   0.0001) in the spine.73 In a subgroup 
analysis based on age, fracture risk reduction was signiﬁ  -
cantly greater in those aged 70 to 79 years (relative risk [RR] 
0.89, 95% CI 0.82–0.96) and those aged  80 years (RR 0.76, 
95% CI 0.67–0.87) compared to those age 50 to 69 years 
(RR 0.97, 95% CI 0.92–1.02), p = 0.003.73 In the same meta-
analysis, calcium doses of  1200 mg per day and vitamin D 
doses of  800 international units (IU) per day were found 
to be statistically better at preventing fractures than lower 
doses (p = 0.006 and p = 0.03, respectively).73
Vitamin D monotherapy in doses between 700 to 800 IU 
per day has also been shown in a meta-analysis to reduce the 
risk of hip and any non-vertebral fractures in ambulatory 
and institutionalized seniors.74 A Cochrane review published 
around the same time found that vitamin D alone showed no 
statistically signiﬁ  cant effect on hip, vertebral or any new 
fracture.75 However, it does not appear that the authors evalu-
ated the data based on the dose of vitamin D. An even more 
recent meta-analysis concluded that oral vitamin D appears 
to reduce the risk of hip fractures only when it is combined 
with calcium supplementation.76 Studies regarding the use of Clinical Interventions in Aging 2009:4 127
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vitamin D supplements to prevent fractures are conﬂ  icting, 
likely because patient populations may have different base-
line 25(OH) vitamin D concentrations, interventions may 
utilize different forms of vitamin D (eg, ergocalciferol vs cho-
lecalciferol), and doses may be different (eg,  800 IU per day
vs  800 IU per day). Unfortunately, none of the studies 
described above performed analyses to evaluate effects based 
on subject age.
The effects of vitamin D monotherapy on falls was evalu-
ated in a meta-analysis that found that vitamin D reduced the 
odds ratio of falling by 22% (corrected odds ratio 0.78, 95% 
CI 0.64–0.092) compared with patients (mean age ranged 
from 70 to 85 years) receiving calcium or placebo.64 Since 
the meta-analysis of vitamin D and falls was published, 
multiple other studies evaluating effects of vitamin D supple-
mentation on falls have been published, most of which are 
positive.65 A prospective, randomized, multi-dose study of 
nursing home residents (mean age 89 years) found that those 
taking 800 IU per day of vitamin D2 supplementation had 
a 72% lower adjusted-incidence rate of falls than those tak-
ing placebo (RR 0.28, 95% CI 0.11–0.75) over 5 months.77 
Patients taking 200 IU per day, 400 IU per day and 600 IU 
per day of vitamin D had similar fall rates to those taking pla-
cebo. A 2005 study of 625 independent and institutionalized 
older seniors (mean age 83 years) found that ergocalciferol 
(10,000 IU weekly then 1000 IU daily) and calcium carbonate 
600 mg daily demonstrated an incident rate ratio of falling 
of 0.73 (95% CI 0.57–0.95) compared to placebo.66 This 
translates to 8 patients treated with vitamin D over 1 year 
to prevent one fall from occurring.66 Two negative studies 
in older seniors (mean ages 85 and 84 years, respectively) 
utilized bolus dosing of ergocalciferol 100,000 units (every 
3 months and every 4 months, respectively), which may 
explain their ﬁ  nding of lack of efﬁ  cacy to prevent falls and 
fractures.78,79 Evidence suggests that large infrequent doses 
of ergocalciferol may provide only short-term beneﬁ  ts, as 
compared to cholecalciferol.65
Although data regarding vitamin D monotherapy might be 
conﬂ  icting regarding fracture and fall reduction, it is apparent 
that combination calcium and vitamin D supplementation is 
beneﬁ  cial for older seniors. In addition, supplementation is 
inexpensive and well-tolerated. Vitamin D3 (cholecalciferol) 
is the preferred formulation for vitamin D supplementation. 
The total daily vitamin D dose can be given via a multi-
vitamin, calcium plus vitamin D, and/or vitamin D alone. 
Often a combination of the products containing vitamin D 
is necessary to achieve adequate 25(OH) vitamin D con-
centrations.
Calcium is typically supplemented utilizing either 
calcium carbonate or calcium citrate. The calcium citrate 
form may be advantageous for older seniors, since calcium 
citrate absorption does not rely on gastric acid like calcium 
carbonate, and older seniors may suffer from achlorhydria. 
Moreover, patients taking proton pump inhibitors (PPIs) may 
beneﬁ  t more from supplementation with calcium citrate. One 
small study found that calcium carbonate absorption was 
inhibited by co-administration with omeprazole.71 Since 
many older seniors may also take a PPI, it may be prudent 
to recommend supplementation with calcium citrate in those 
patients. In addition, it may be appropriate to assess the need 
of the PPI, as long-term treatment with PPIs has been associ-
ated with increased risk of hip fracture.72 It is not known if 
the increased risk of hip fracture is due to the effect of PPIs 
on calcium absorption.
Calcium and vitamin D supplementation in the older 
senior is well tolerated, other than possible constipation 
associated with the calcium component. Hypercalcemia 
and hyperphosphatemia rarely occur. Vitamin D toxicity 
is extremely rare and usually only occurs with long-term 
administration of extremely high doses, such as 50,000 IU 
per day or more.35 Currently, the tolerable upper intake level 
of vitamin D is set at 2000 units per day, although with 
proper monitoring older seniors may beneﬁ  t from higher 
doses. Doses of vitamin D should be titrated to achieve a 
serum 25(OH) vitamin D concentration of 75 to 150 nmol/L 
(30–60 ng/mL) to fully maximize calcium absorption and 
beneﬁ  ts on BMD and muscles.35
Drug therapy
The 2008 National Osteoporosis Foundation (NOF) 
Clinician’s Guide recommends treatment of postmeno-
pausal women and men 50 years of age or older with (1) 
a hip or vertebral fracture, (2) a femoral neck, total hip, or 
spine T-score of –2.5 or less measured by central DXA, or 
(3) a T-score between –1.0 and –2.5 measured by central 
DXA (ie, osteopenia) and other prior fractures, a secondary 
cause associated with a high risk of fractures, a 10-year hip 
fracture probability of 3% or higher, or a 10-year prob-
ability of major osteoporosis-related fracture (vertebral, 
hip, forearm, or humerus fracture) of 20% or higher.5 
These probabilities are calculated using the WHO FRAX 
tool.56 According to this guideline all older seniors with 
the diagnosis of osteoporosis would warrant drug therapy. 
In addition, using the US FRAX to calculate the 10-year 
probability for fracture, the majority of Caucasian women 
80 years of age or older would meet criteria for treatment at Clinical Interventions in Aging 2009:4 128
Vondracek and Linnebur
a T-score of –1.7 or less even in the absence of additional 
clinical risk factors.
The NOF Clinicians Guide is more aggressive in recom-
mending drug therapy in the older senior compared to other 
Guidelines. The National Osteoporosis Guideline Group 
from the UK published in 2008 recommendations for the 
prevention and treatment of osteoporosis in postmenopausal 
women and men age   50 years.80 They recommend age-
based treatment thresholds using the 10-year probability of 
a major osteoporotic fracture from the UK speciﬁ  c FRAX 
tool. According to this guideline, the intervention threshold 
for an 80-year-old man with or without previous fracture and 
an 80-year-old postmenopausal woman with no previous 
fracture would be a 10-year probability of major osteoporotic 
fracture of at least 30%. An updated list of National and 
Regional Osteoporosis Guidelines can be found at the Inter-
national Osteoporosis website: http://www.iofbonehealth.
org/health-professionals/national-regional-guidelines/
evidence-based-guidelines.html.
Drug therapy for the management of osteoporosis in the 
older senior is summarized in Table 4.81–105 The majority 
of pharmacological interventions available are considered 
antiresorptive (bisphosphonates, calcitonin, raloxifene, and 
hormone replacement therapy). Only parathyroid hormone is 
considered truly anabolic or bone building. The mechanism 
of action of strontium ranelate is not completely understood, 
but is thought to reduce bone resorption while maintaining 
bone formation. All these interventions have been shown to 
reduce the risk of vertebral fracture when given with calcium 
and vitamin D supplements. Some have been shown to also 
reduce the risk of non-vertebral fractures and speciﬁ  cally hip 
fractures.81,88,89,93,99 Intravenous zoledronic acid may reduce 
mortality in patients with a previous hip fracture.92
When deciding whether or not to institute drug therapy 
for the management of osteoporosis in the older senior, 
several factors need to be taken into consideration. First it 
is important to determine if there is evidence to support a 
beneﬁ  t from osteoporosis therapy in the older senior. In 2003, 
the average additional life span for a 75-year-old in the US 
was 11.8 years and for an 85-year-old was 6.8 years.106 Data 
for most osteoporosis therapies show signiﬁ  cant decreases in 
vertebral fracture rates as early as 6 months to 1 year.93,107,108 
Unless there is a comorbid condition that is expected to 
signiﬁ  cantly reduce life expectancy, many older seniors 
will live long enough to potentially derive a beneﬁ  t from 
osteoporosis drug therapy.
Similar to other disease states, efﬁ  cacy data are lacking in 
the older senior population, with the majority of information 
coming from post hoc subgroup analyses. In an analysis of 
data from the Fracture Intervention Trial with alendronate, 
the relative risk reductions for clinical fractures at the hip, 
spine and wrist with alendronate therapy were found to be 
constant across all age groups up to the age of 85 years.109 
The absolute risk reduction (ARR) between alendronate and 
placebo increased with increasing age. For example, the ARR 
for hip fracture was 11 per 10,000 person-years for women 
55 to 64 years of age and 53 per 10,000 person-years for 
women 75 to 85 years of age. Comparable results were seen 
in a post hoc analysis by Ensrud and colleagues.57 Statistically 
signiﬁ  cant relative risk reductions in new vertebral fractures 
were seen with alendronate therapy compared to placebo 
both in women  75 years of age (relative risk [RR] = 0.49; 
95% CI, 0.35–0.68) and 75 to 82 years of age (RR = 0.62; 
95% CI, 0.41–0.94).
Pivotal studies of risedronate compared to placebo did not 
exclude subjects based on age. A pooled analysis of data from 
these studies demonstrated a statistically signiﬁ  cant 44% 
relative risk reduction for new vertebral fractures at 3 years 
with risedronate therapy in women between 80 and 100 years 
of age (HR = 0.56, 95% CI = 0.39–0.81, p = 0.03).110 There 
was no signiﬁ  cant difference in non-vertebral fracture risk 
between risedronate and placebo in the population. Rise-
dronate is the only oral therapy to be evaluated in a large, 
prospective clinical trial with hip fracture reduction as the 
primary endpoint.88 Postmenopausal women were enrolled 
into two arms. The osteoporosis arm included women aged 
70 to 79 years with documented osteoporosis. The risk factor 
arm included women 80 years and older (mean age 83 years) 
with either one non-skeletal risk factor for hip fracture or 
osteoporosis. The majority of the subjects in this arm did not 
have central DXA results and were enrolled based on risk 
factors for fall. Overall, risedronate reduced the risk of hip 
fractures by 30% (RR = 0.70, 95% CI, 0.6–0.69). However, 
when the two groups were evaluated independently, the 
incidence of hip fracture was not signiﬁ  cantly reduced in the 
risk factor arm (RR = 0.8, 95% CI, 0.6–1.2).
The HORIZON-Pivotal Fracture Trial (PFT) compared 
zoledronic acid infused intravenously once-yearly to pla-
cebo on vertebral and hip fracture risk in postmenopausal 
women with osteoporosis.93 A post hoc analysis of results 
stratiﬁ  ed according to age groups ( 70 years, 70–74 years 
and  75 years) demonstrated that new vertebral and non-
vertebral fractures were signiﬁ  cantly reduced in all age 
groups.111 In this analysis, the relative risk for new verte-
bral fractures were reduced by 60% (p   0.001) in those 
women   75 years of age compared to 80% (p   0.001) Clinical Interventions in Aging 2009:4 129
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in those  70 years of age. Hip fracture risk was only 
signiﬁ  cantly reduced in the  70 years age group (RR = 0.30; 
p   0.05). The HORIZON-Recurrent Fracture Trial (RFT) 
randomized men and women with a prior hip fracture to 
receive once yearly intravenous infusions of zoledronic 
acid.92 Over 50% of the subjects enrolled were 75 years of 
age or older. A statistically signiﬁ  cant 35% reduction in any 
clinical fracture (p = 0.001) and 28% reduction in all cause 
mortality (p = 0.01) was demonstrated in the treatment group 
compared to placebo. The reduction in hip fracture risk did 
not reach statistical signiﬁ  cance.
An analysis of the Fracture Prevention Trial with teripa-
ratide demonstrated a similar beneﬁ  t with therapy compared 
to placebo in younger and older women.112,113 For women 
younger than 75 years and those aged 75 years and older, 
teriparatide therapy resulted in an ARR for new vertebral 
fracture of 9.2% (RR = 0.35, p   0.01) and 9.9% (RR = 0.35, 
p   0.05), respectively compared to placebo.112 Non-vertebral 
fracture risk was not signiﬁ  cantly reduced in the  75 years 
of age group with teriparatide therapy (RR = 0.75, p = 0.66). 
However, the treatment-by-age interaction (p = 0.42) indicated 
that the effect of teriparatide on non-vertebral fractures was not 
signiﬁ  cantly different between those  75 or those  75 years 
of age.
A pre-planned pooled analysis of studies with oral 
strontium ranelate compared to placebo evaluated efﬁ  cacy 
in women with osteoporosis who were between the age of 
80 and 100 years (mean age 84 years).114 Over 3 years, the 
relative risk for vertebral and non-vertebral fractures was sig-
niﬁ  cantly reduced by 32% (p = 0.013) and 31% (p   0.011), 
respectively in the strontium-treated patients. Hip fracture 
risk reduction did not reach statistical signiﬁ  cance (32%, 
p = 0.112).
The Multiple Outcomes of Raloxifene Evaluation 
(MORE) study enrolled postmenopausal women age 31 to 
80 years.94 The mean age of the study subjects was 67 years. 
Subgroup analyses based on age are not available.
The Women’s Health Initiative evaluated the effects of 
estrogen with or without progestin on several chronic disease 
states including fractures in healthy postmenopausal women 
age 50 to 79 years.104,105 Reductions in clinical vertebral and 
hip fractures were seen, and the results did not differ with age 
stratiﬁ  cation. Hormone replacement therapy is only indicated 
in the US for the prevention of osteoporosis and should not 
be used solely for this purpose.5
Subgroup analyses, while not ideal, have consistently 
demonstrated a signiﬁ  cant reduction in vertebral fracture 
risk with drug therapy across all age groups. The inconsistent 
beneﬁ  t seen in non-vertebral fracture risk in older patients 
may be due to the fact that improvement in bone strength is 
overshadowed by increasing fall risk in this population.
Only one study has been prospectively designed to 
evaluate the efﬁ  cacy of therapy in the older patient (mean 
age 78.5 years; range 65–91 years) residing in a long-term 
care facility. In this study, alendronate 10 mg po once daily 
for 2 years signiﬁ  cantly increased BMD at the hip and spine 
compared to placebo, with no difference in adverse events 
between groups.115 Fracture risk was not evaluated in this 
study.
Intranasal calcitonin is frequently prescribed in the older 
senior population, possibly due to its benign side effect proﬁ  le 
and ease of administration.22 Calcitonin has not been shown 
to improve hip BMD or reduce hip fracture risk.97 Based 
on vertebral fracture efﬁ  cacy, it is considered a third line 
therapy option for osteoporosis management. Efﬁ  cacy data 
are not available for the older senior; however in the Prevent 
Recurrence of Osteoporotic Fractures study, 21% to 25% of 
the women enrolled were  75 years of age.97
Some evidence suggests that calcitonin may have an anal-
gesic effect. Small studies have demonstrated a short-term 
beneﬁ  t from calcitonin therapy on pain in senior men and 
women who have suffered an acute vertebral compression 
fracture.98,116,117 The short-term (∼4 weeks) administration of 
intranasal calcitonin for pain relief should not preclude the 
use of more efﬁ  cacious therapies, such as bisphosphonates, 
for the treatment of osteoporosis.
Limited studies have evaluated the beneﬁ  t of pharmacologic 
treatment in men.118–123 The mean age of the subjects in the 
majority of the studies was  65 years.118,121–123 While small 
in size, these studies did demonstrate improvements in BMD 
similar to studies in postmenopausal women and two studies 
showed signiﬁ  cant reductions in vertebral fracture risk.121,123 
Two studies have evaluated the effect of risedronate on hip 
fracture risk in older men. In 280 men post stroke (mean age 
76 years), 2.5 mg risedronate daily signiﬁ  cantly reduced hip 
fracture risk by 81% (RR = 0.19, 95% CI, 0.04–0.89) com-
pared to placebo.119 In 223 men with Parkinson’s Disease 
(mean age = 71.3 years; range 65 to 85), 2.5 mg risedronate 
daily did not signiﬁ  cantly reduce hip fracture risk compared 
to placebo (RR = 0.33; 95% CI, 0.09–1.20).120 More studies 
are needed to fully understand the beneﬁ  ts and risks of 
osteoporosis therapy in older men.
In addition to efﬁ  cacy, one needs to consider the risks 
of pharmacological treatment in the older senior. Admin-
istration of oral bisphosphonates, which are considered 
ﬁ  rst line therapy for osteoporosis, can be challenging in Clinical Interventions in Aging 2009:4 130
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the older senior. To ensure adequate absorption, patients 
cannot eat, drink (other than plain water), or consume any 
medications for 30 to 60 minutes after taking a bisphospho-
nate. To reduce the risk for esophageal side effects, patients 
need to take the medication with at least 180 to 240 mL 
(6–8 ounces) of plain water and be able to sit upright for at 
least 30 to 60 minutes after taking. These instructions can 
be especially difﬁ  cult for institutionalized or cognitively 
impaired seniors. A signiﬁ  cant number of seniors have gas-
trointestinal complaints, which are the most common side 
effects of oral bisphosphonates. While clinical trial data do 
not indicate an increased risk for side effect in older sub-
jects compared to younger subjects, real-world experience 
indicates an increased risk of these effects if the medication 
is not taken appropriately.110,124 A recent letter to the edi-
tor summarizes US Food and Drug Administration (FDA) 
reports of esophageal cancer diagnoses in patient taking oral 
bisphosphonates.125 It is possible that inappropriate adminis-
tration contributed to some of these cases. The older senior 
is frequently on multiple oral medications. The addition 
of an oral osteoporosis medication (including calcium and 
vitamin D) can add complexity to an already challenging 
medication regimen leading to potential adherence problems. 
Adherence at one year is poor with these agents and studies 
have demonstrated a reduced fracture beneﬁ  t in patients with 
poor adherence.126–128
Intravenous bisphosphonates are an option in the older 
senior who cannot tolerate or may have difﬁ  culty adhering 
to oral bisphosphonate therapy. Quarterly intravenous injec-
tions of ibandronate or a once yearly infusion of zoledronic 
acid may signiﬁ  cantly improve adherence in this popula-
tion. The most common side effects are short-term ﬂ  u-like 
symptoms (eg, myalgias, arthralgias, pyrexia).91–93 In the 
HORIZON-PFT, an increased incidence of serious atrial 
ﬁ  brillation was observed in the zoledronic acid group (1.3%) 
compared to placebo (0.5%), p   0.001.92,93 No plausible 
biological explanation could be found. In addition, the rates 
of atrial ﬁ  brillation were similar between the zoledronic acid 
and placebo groups in the HORIZON-RFT.92 The risk for 
atrial ﬁ  brillation increases with age. A possible increased 
risk for atrial ﬁ  brillation with bisphosphonates therapy could 
be a concern in the older senior. Due to conﬂ  icting evidence 
on the link between atrial ﬁ  brillation and the use of bisphos-
phonates,129–131 the FDA conducted a review of all safety data 
and concluded that there was “no clear association between 
overall bisphosphonate exposure and the rate of serious or 
non-serious atrial ﬁ  brillation. Increasing dose or duration 
of bisphosphonate therapy was also not associated with an 
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increased rate of atrial ﬁ  brillation.” The FDA is continuing 
to monitor postmarket reports of atrial ﬁ  brillation in patients 
who have taken bisphosphonates.
Raloxifene, an estrogen agonist-antagonist, is considered 
a second line option for the management of osteoporosis in 
older seniors and is FDA-approved in the US for use in post-
menopausal women at high risk for invasive breast cancer.132 
It is administered orally on a daily basis, which may result in 
lower adherence compared with less frequently administered 
bisphosphonates. Side effects are also a concern with this 
therapy as raloxifene has been shown to increase venous 
thromboembolism risk by 3-fold and fatal stroke risk (1.2% 
raloxifene vs 0.8% placebo, p = 0.0499).95,96
Teriparatide and parathyroid hormone 1–84 are admin-
istered by subcutaneous injection once daily. They are an 
option for patients that are at high risk for fracture or who 
cannot tolerate or fail other therapies. While side effects are 
limited (ﬁ  rst dose dizziness and transient hypercalcemia), 
daily administration of these therapies in the older senior 
can be challenging.
Special considerations
Kidney function or glomerular ﬁ  ltration rate (GFR) declines 
with aging. Many older seniors with osteoporosis have 
estimated GFRs of  60 mL/min and some  30 mL/min 
without any evidence for kidney damage.133,134 According to 
package labeling, oral and iv bisphosphonates are not recom-
mended for patients with a creatinine clearance (CrCl)   30 
or 35 mL/min. Approximately 50% of the absorbed dose 
of a bisphosphonate is excreted unchanged by the kidney; 
therefore, reductions in kidney function have the potential to 
result in accumulation of the bisphosphonate. It is important 
to know if bisphosphonates are efﬁ  cacious and safe to use in 
the older senior with reduced kidney function.
The inﬂ  uence of baseline kidney function on the safety 
and efﬁ  cacy of once daily risedronate was evaluated in a 
retrospective analysis of data from 9 randomized, double-
blind, placebo-controlled trials.135 CrCl was estimated 
using the Cockcroft and Gault method. There was no dif-
ference in side effect rates or the risk for vertebral fractures 
among patients with mild (CrCl 50–79 mL/min), moderate 
(CrCl 30–49 mL/min) or severe kidney impairment 
(CrCl 15–30 mL/min). The mean age of the patients in the 
severe kidney impairment group was 83 years compared to 
71 years in the mild group.
In a study using data with teriparatide, postmenopausal 
women with impaired kidney function (CrCl 30–79 mL/min) 
had comparable rates of adverse events, increases in BMD, 
and decreases in vertebral and non-vertebral fracture risk 
as postmenopausal women with normal kidney function 
(CrCl   80 mL/min).136 Alendronate also demonstrated simi-
lar efﬁ  cacy in postmenopaual women with reduced kidney 
function (CrCl   45 mL/min) as women without reduced 
kidney function.137
The efﬁ  cacy and safety of raloxifene by degree of kidney 
impairment was examined using data from the MORE 
trial.138 This post hoc analysis demonstrated raloxifene 
was effective and well tolerated in patients with mild to 
moderate kidney impairment (mean CrCl  40 mL/min). 
Package labeling indicates raloxifene should be used with 
caution in patients with moderate or severe renal impair-
ment since safety and efﬁ  cacy have not been established. 
Based on the results of these studies, teriparatide may be an 
option for older seniors with moderate kidney impairment 
(CrCl 30–49 mL/min) and oral bisphosphonates, speciﬁ  cally 
risedronate, in older seniors with severe age-related kidney 
impairment (CrCl as low as 15 mL/min). There are no data 
regarding safety and efﬁ  cacy of intravenous bisphospho-
nates in patients with severe kidney impairment, but those 
with a CrCl   30 mL/min were included in the HORIZON 
studies. Renal safety of zoledronic acid was evaluated in 
the HORIZON studies. A signiﬁ  cant increase in serum 
creatinine of more than 0.5 mg/dL occurred at 9 to 11 days 
after infusion in 1.2% of the treatment group compared 
to 0.4% of the placebo group (p   0.001) in HORIZON-
PFT.93 There was no difference between groups in serum 
creatinine or CrCl at the end of the study. In addition, no 
signiﬁ  cant increase in serum creatinine was noted in the 
HORIZON-RFT.92
Conclusion
The older senior is at high risk for osteoporosis. Bone min-
eral density testing with central DXA is essential and cost-
effective in this population. Based on subgroup analyses of 
large osteoporosis trials in postmenopausal women, current 
osteoporosis therapies appear safe and efﬁ  cacious in the older 
senior and most will live long enough to derive a beneﬁ  t 
from these therapies. The risk for vitamin D insufﬁ  ciency 
and deﬁ  ciency is high and should be treated appropriately. 
It is important to remember that falls play a very important 
role in the risk for osteoporosis fractures, especially in the 
older senior. Strategies to reduce fall risk in this population 
will be just as important as pharmacological therapy. Further 
studies are needed in older seniors, especially men, to better 
understand the risks and beneﬁ  ts of pharmacologic therapy 
for the management of osteoporosis.Clinical Interventions in Aging 2009:4 133
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